Wilson Sonsini Goodrich & Rosati advised SpectraWAVE on the transaction. SpectraWAVE, Inc., a medical imaging company, has announced raising $50 million in Series B funding round...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Tempo Therapeutics in the transaction. Tempo Therapeutics, Inc. (“Tempo”) announced the completion of a $12 million Series A equity financing round, led by...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati provided IP and corporate counsel to DermBiont in the transaction. DermBiont announced its $35.2 million Series B financing. The financing was led...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Ascidian Therapeutics on the deal. Life sciences venture capital firm ATP announced the launch of new biotechnology company Ascidian Therapeutics....
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Arena Pharmaceuticals, Inc. and Aristea Therapeutics, Inc. announced a strategic collaboration to advance the clinical...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Aristea announced the closing of a $63 million Series B financing led by Fidelity Management &...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Ventyx Biosciences on the deal. Taylor Wessing advised Oppilan Pharma Limited and Zomagen Biosciences Limited. Ventyx Biosciences, a clinical-stage biotechnology...
You must be a Standard 1 Year member to access this content.
